EBS:NYE-Emergent Biosolutions Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 7.71

Change

-0.13 (-1.66)%

Market Cap

N/A

Volume

1.30M

Analyst Target

USD 112.29
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-21 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+3.04 (+1.93%)

USD 74.41B
TAK Takeda Pharmaceutical Co Ltd A..

+0.20 (+1.44%)

USD 43.37B
HLN Haleon plc

+0.18 (+1.82%)

USD 43.18B
RDY Dr. Reddy’s Laboratories Ltd..

-0.09 (-0.67%)

USD 11.49B
ELAN Elanco Animal Health

-0.11 (-0.99%)

USD 5.69B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.04 (-0.51%)

USD 3.63B
BHC Bausch Health Companies Inc

+0.13 (+1.81%)

USD 2.41B
DHBUF Delivra Health Brands Inc

+0.11 (+744.67%)

USD 5.54M
CPHI China Pharma Holdings Inc

-0.01 (-4.59%)

USD 3.69M
YCBD cbdMD Inc

+0.01 (+1.47%)

USD 1.96M

ETFs Containing EBS

EMUM:SW iShares MSCI EMU Mid Cap .. 2.10 % 0.00 %

+0.42 (+-0.49%)

USD 0.16B
LDEG:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

+4.30 (+-0.49%)

N/A
LGGE:XETRA 1.30 % 0.00 %

N/A

N/A
LDEU:LSE L&G Quality Equity Divide.. 1.20 % 0.00 %

+0.07 (+-0.49%)

USD 0.04B
PRFZ Invesco FTSE RAFI US 1500.. 0.33 % 0.39 %

-1.14 (-0.49%)

USD 2.62B
IWSZ:SW iShares Edge MSCI World S.. 0.15 % 0.00 %

N/A

USD 0.28B
FDT First Trust Developed Mar.. 0.00 % 0.80 %

-0.62 (-0.49%)

USD 0.43B
FEP First Trust Europe AlphaD.. 0.00 % 0.80 %

-0.29 (-0.49%)

USD 0.20B
FEUZ First Trust Eurozone Alph.. 0.00 % 0.80 %

-0.39 (-0.49%)

USD 0.02B
EUMD:LSE iShares MSCI Europe Mid C.. 0.00 % 0.00 %

+0.01 (+-0.49%)

USD 0.32B
FEUZ:LSE First Trust Eurozone Alph.. 0.00 % 0.00 %

-1.50 (-0.49%)

USD 0.05B
FEUD:LSE First Trust Eurozone Alph.. 0.00 % 0.00 %

-1.50 (-0.49%)

USD 0.02B
IS3H:F 0.00 % 0.00 %

N/A

N/A
C005:XETRA 0.00 % 0.00 %

N/A

N/A
EL43:XETRA 0.00 % 0.00 %

N/A

N/A
IS3H:XETRA 0.00 % 0.00 %

N/A

N/A
IS3T:XETRA 0.00 % 0.00 %

N/A

N/A
FTEU:LSE First Trust Eurozone Alph.. 0.00 % 0.00 %

-0.01 (-0.49%)

USD 0.05B
FTGE:XETRA 0.00 % 0.00 %

N/A

N/A
BINV 2023 ETF Series Trust - B.. 0.00 % 0.00 %

-0.16 (-0.49%)

USD 0.16B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.35% 13% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.35% 13% F 3% F
Trailing 12 Months  
Capital Gain 181.39% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 181.39% 100% F 99% N/A
Trailing 5 Years  
Capital Gain -88.31% 23% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -88.31% 23% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -8.59% 14% F 7% C-
Dividend Return -8.59% 14% F 6% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 128.31% 21% F 7% C-
Risk Adjusted Return -6.70% 36% F 17% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector